86 related articles for article (PubMed ID: 16402084)
1. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics.
Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
Pharmacogenomics J; 2006; 6(3):174-8. PubMed ID: 16402084
[TBL] [Abstract][Full Text] [Related]
2. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
3. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
[TBL] [Abstract][Full Text] [Related]
4. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
6. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers.
Schwartz SG; Puckett BJ; Allen RC; Castillo IG; Leffler CT
Ophthalmology; 2005 Dec; 112(12):2131-6. PubMed ID: 16325708
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population.
Mahesh Kumar KN; Ramu P; Rajan S; Shewade DG; Balachander J; Adithan C
J Cardiovasc Pharmacol; 2008 Nov; 52(5):459-66. PubMed ID: 19033826
[TBL] [Abstract][Full Text] [Related]
8. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
9. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
Pharmacotherapy; 2006 Sep; 26(9):1247-54. PubMed ID: 16945046
[TBL] [Abstract][Full Text] [Related]
10. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
[TBL] [Abstract][Full Text] [Related]
11. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
12. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
Johnson JA; Zineh I; Puckett BJ; McGorray SP; Yarandi HN; Pauly DF
Clin Pharmacol Ther; 2003 Jul; 74(1):44-52. PubMed ID: 12844134
[TBL] [Abstract][Full Text] [Related]
13. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
14. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy.
Biolo A; Clausell N; Santos KG; Salvaro R; Ashton-Prolla P; Borges A; Rohde LE
Am J Cardiol; 2008 Sep; 102(6):726-32. PubMed ID: 18773997
[TBL] [Abstract][Full Text] [Related]
15. Cardiac reserve in the transplanted heart: effect of a graft polymorphism in the beta1-adrenoceptor.
Scharin Täng M; Lindberg E; Grüner Sveälv B; Magnusson Y; Andersson B
J Heart Lung Transplant; 2007 Sep; 26(9):915-20. PubMed ID: 17845930
[TBL] [Abstract][Full Text] [Related]
16. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.
Terra SG; Hamilton KK; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hill JA; Aranda JM; Yarandi HN; Johnson JA
Pharmacogenet Genomics; 2005 Apr; 15(4):227-34. PubMed ID: 15864115
[TBL] [Abstract][Full Text] [Related]
17. Effect of the Arg389Gly β₁-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Hjelvang BR; Henriksen T; Frandsen E; Forman JL; Torp-Pedersen C; Køber L; Poulsen HE
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):779-85. PubMed ID: 22703382
[TBL] [Abstract][Full Text] [Related]
18. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment.
Suonsyrjä T; Donner K; Hannila-Handelberg T; Fodstad H; Kontula K; Hiltunen TP
Pharmacogenet Genomics; 2010 May; 20(5):342-5. PubMed ID: 20300048
[TBL] [Abstract][Full Text] [Related]
19. The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease.
Defoor J; Martens K; Zielinska D; Matthijs G; Van Nerum H; Schepers D; Fagard R; Vanhees L
Eur Heart J; 2006 Apr; 27(7):808-16. PubMed ID: 16421173
[TBL] [Abstract][Full Text] [Related]
20. Applicability of microdialysis as a technique for pharmacokinetic-pharmacodynamic (PK-PD) modeling of antihypertensive beta-blockers.
Höcht C; DiVerniero C; Opezzo JA; Taira CA
J Pharmacol Toxicol Methods; 2005; 52(2):244-50. PubMed ID: 16125622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
